Streetbeat News

Products Services

DAL

EIS

SPY

Delta Air Lines is adding three flights to return Israel evacuees to the U.S. The company is working with the U.S. Department of State and monitoring bookings on these new flights to determine if additional seats are needed.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:31 pm

AMZN

PlayersTV, a network owned by over 50 athletes, has launched on Amazon's Prime Video and Amazon Freevee as a free ad-supported streaming television (FAST) Channel. The expansion is marked by the premiere of “Vino Talk,” a new series hosted by NBA Champion Deandre Jordan and professional softball player and sports broadcaster, AJ Andrews. The partnership with Amazon is expected to increase PlayersTV's reach and enhance its mission to highlight the human aspects of sports.

Portfolio Pulse from Javier Hasse

October 13, 2023 | 7:29 pm

Ford Motor is contemplating reducing a work shift at the plant where it manufactures its electric F-150 Lightning pickup due to declining demand, as per a United Auto Workers official's memo. Sales of the electric truck have dropped in recent months after a strong start.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:25 pm

AAPL

AMZN

BBY

DIS

NFLX

Best Buy Co., Inc. (BBY) plans to discontinue in-store and online DVDs starting in 2024. The decision won't affect video games. The move follows Netflix, Inc. (NFLX) ending its DVD subscription service. The availability of streaming services like Walt Disney Company (DIS), Hulu, Amazon.Com, Inc. (AMZN), and Apple Inc. (AAPL) has led to DVDs becoming nearly obsolete. Entertainment represents just 6% of Best Buy's total revenue in the U.S.

Portfolio Pulse from Nabaparna Bhattacharya

October 13, 2023 | 7:14 pm

BIIB

ESALY

LLY

The U.S. Centers for Medicare and Medicaid Services has revised its policy to permit multiple uses of amyloid PET scans, a tool for Alzheimer's diagnosis. This change aligns with the eligibility criteria for new Alzheimer's drugs and benefits patients seeking access to such drugs, including Eisai Co Ltd/Biogen Inc's Leqembi and Eli Lilly And Co's experimental drug, donanemab. The policy change also ensures government reimbursement for drugs like Leqembi by confirming the presence of amyloid in the brain.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 7:10 pm

PARA

PARAA

President Joe Biden will be interviewed on '60 Minutes', a show aired on CBS, a unit of Paramount Global (NASDAQ:PARA)(NASDAQ:PARAA). The interview will cover a range of topics including the current state of America and the world, the Middle East conflict, and the 2024 presidential election. The president's views on the economy and inflation are also expected to be discussed.

Portfolio Pulse from Chris Katje

October 13, 2023 | 6:58 pm

PSQH

PSQ Holdings Inc reported strong preliminary Q3 results, with revenue growth of over 300% Q/Q and 1,600% Y/Y to $2.2 million. The company's direct-to-consumer pro-life baby care brand, EveryLife, contributed significantly to this growth. PSQ ended Q3 with over $25 million cash and expects its first profitable quarter in 2024. The company plans to roll out its eCommerce shopping experience in November and launch PSQLink, a business management tool, this month.

Portfolio Pulse from Lekha Gupta

October 13, 2023 | 6:12 pm

RVMD

Revolution Medicines Inc (NASDAQ:RVMD) released preliminary data for its RMC-6236 and RMC-6291 cancer drugs from Phase 1/1b studies. The data, presented at the 2023 AACR-NCI-EORTC International Conference, showed promising results with acceptable safety profiles and evidence of clinical activity. Following the news, RVMD shares rose by 20.30%.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 6:09 pm

NCNA

NuCana plc (NASDAQ:NCNA) presented data from two ongoing clinical studies with NUC-3373 in colorectal cancer at the AACR-NCI-EORTC International Conference. The data showed promising anti-tumor activity and a favorable safety profile. The NuTide:302 study showed that patients receiving NUC-3373-based regimens achieved a longer progression-free survival compared to their first-line treatment with 5-FU-based therapy. The ongoing Phase 2 NuTide:323 study is recruiting well with no new safety signals.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 4:32 pm

KRON

Kronos Bio, Inc. (NASDAQ:KRON) has announced positive preliminary data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 clinical trial of KB-0742 at the AACR-NCI-EORTC International Conference. KB-0742 is being developed to treat transcriptionally addicted solid tumors. The preliminary analysis included 28 patients who received doses from 10 mg up to 60 mg. KB-0742 demonstrated on-mechanism single agent anti-tumor activity and exhibited a manageable safety profile. The maximum tolerated dose has not yet been identified, and dosing of patients at the 80 mg dose level is underway.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 4:31 pm